Kigtropin ist der Markenname für synthetisch hergestellte Menschen,Kigtropin ist das beste Somatropin HGH auf dem Markt, die effektivsten und besten Ergebnisse, die eine Person erzielen kann, Kigtropin wird entwickelt. Wir versenden die Bestellung aus den USA, Chyna, und EU. Wir sind ein Vertriebspartner von?Kigtropin HGH Großhändler von? Kigtropin HGH, Bitte erhalten Sie mehr Kigtropin HGH China (Festland) Hersteller, Exporteure, Lieferanten, Fabriken, Unternehmen aus China .
Kigtropin ist ein menschliches Wachstumshormon (hGH) Somatropin wird mit rekombinanter DNA-Technologie hergestellt, die mit dem natürlich produzierten HGH des Körpers identisch ist.
Wachstumsstörung von Kindern aufgrund eines endogenen Wachstumshormonmangels (GHD).
Bei Erwachsenen mit Wachstumshormonmangel,KIGTROPIN reduziert die Fettmasse,erhöht die Muskelmasse und verbessert die Energie,Vitalität und subjektives Wohlbefinden. Bei Patienten mit schweren Verbrennungen,AIDS assoziierter Muskelschwund,oder großen Operationen unterzogen werden,KIGTROPIN fördert die Wundheilung,dämpft die proteinkatabole Reaktion und verbessert den Stickstoffzustand des ganzen Körpers nach der Operation.
Kigtropin comes as a freeze dried white powder – 10 x 10 IU (3.3 mg) vials per box. Like several others it started as a made up brand name which became popular due to good reviews in the bodybuilding community. It is manufactured by an unknown Chinese lab – which seems to be a common practice some Chinese companies use to avoid the HGH legality issues
In patients who continue growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2 - 0.5 Milligramm pro Tag. The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.
In adults with adult-onset GHD, therapy should start with a low dose, 0.15 - 0.3 Milligramm pro Tag. The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.
In both cases treatment goal should be insulin-like growth factor (IGF-I) concentrations within 2 SDS from the age corrected mean. Patients with normal IGF-I concentrations at the start of the treatment should be administered growth hormone up to an IGF-I level into the upper range of normal, not exceeding the 2 SDS. Clinical response and side effects may also be used as guidance for dose titration. It is recognized that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation. The maintenance dose rarely exceeds 1.0 Milligramm pro Tag. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. The accuracy of the growth hormone dose should therefore be controlled every 6 months. As normal physiological growth hormone production decreases with age, dose requirements may be reduced.
Kigtropin for Elderly:
In patients above 60 Jahre, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements. The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5 Milligramm pro Tag.
How to Inject:
The subcutaneous administration of growth hormone may lead to loss or increase of adipose tissue at the injection site. Therefore, injection sites should be alternated.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
